Targinta selects ADC-antibody TARG9 as drug candidate

The oncology company Targinta AB, a wholly owned subsidiary of Xintela AB (publ), today announces the selection of the drug candidate TARG9, a conjugated antibody, or ADC (antibody-drug conjugate), targeting the cancer marker integrin α10β1. The candidate, being developed against triple-negative breast cancer and glioblastoma, now enters preclinical development.

TARG9 consists of an integrin α10-antibody linked to a powerful toxin that kills cancer cells expressing the target. The drug candidate is based on the new generation of toxin-conjugation technologies. This so-called ADC-technology is based on more powerful toxins that remain firmly attached to the antibody while circulating. The toxin is released only when TARG9 is taken up into cancer cells expressing integrin α10β1. Since the cancer marker has low expression in normal tissue, the cell-killing effect becomes selective for overexpressing cancers such as triple-negative breast cancer and the aggressive brain cancer glioblastoma. TARG9 was selected after extensive evaluation performed partly under a Vinnova grant, confirming its excellent properties for successful drug development. The drug candidate now enters the preclinical development phase.

“The selection of TARG9 as the company’s first ADC is a truly important milestone and establishes Targinta as a leading Nordic player within the hot ADC field. With an innovative product against a novel cancer target with comprehensive patent protection around both the product and the target, our ambition is to enter into early partnerships to accelerate the development of TARG9, thus contributing to new and better treatment opportunities for cancer patients”, says Per Norlén, CEO at Targinta.

For further information please contact:
Per Norlén, CEO Targinta AB
Email: per.norlen@targinta.se
Phone: +46 46 275 65 00

About Targinta

Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin α10β1. The pipeline includes TARG10, a function-blocking intergrin α10-antibody that is being developed to prevent metastasis, and TARG9, an intergrin α10-ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit www.targinta.se.

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela’s Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

Targinta selects ADC-antibody TARG9 as drug candidate

Targinta selects ADC-antibody TARG9 as drug candidate

Dela:

Facebook
X
LinkedIn